Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cystic fibrosis transmembrane regulator protein mutations: 'class' opportunity for novel drug innovation.

Paediatric drugs - 1 Jan 2007

MacDonald Kelvin D, McKenzie Karen R, Zeitlin Pamela L

Abstract excerpt

Cystic fibrosis (CF) is the most common autosomal, recessive, life-span shortening disease in Caucasians. Since discovery of the gene for CF (cystic fibrosis transmembrane conductance regulator [CFTR]) in 1989, knowledge of the molecular function of this gene and its interactions has offered new therapeutic targets. New therapeutics aimed at improving mutant CFTR protein function, also known as 'protein repair...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cystic Fibrosis
Share to Cystic Fibrosis Transmembrane Conductance Regulator

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Design

Share to CFTR gene

Share to Models, Biological

Share to Mutant Proteins

Share to Mutation

Source

Identifiers

PMID: 17291132
DOI: 10.2165/00148581-200709010-00001

Genes

CFTR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cystic fibrosis transmembrane regulator protein mutations: 'class' opportunity for novel drug innovation.PMID 17291132Read ↗

Cystic fibrosis transmembrane conductance regulator modulators for personalized drug treatment of cystic fibrosis: progress to date.Semantic proximity Read ↗

Genetics of cystic fibrosis: CFTR mutation classifications toward genotype-based CF therapies.Semantic proximity Read ↗

Repairing mutated proteins--development of small molecules targeting defects in the cystic fibrosis transmembrane conductance regulator.Semantic proximity Read ↗

Therapeutic pipeline for individuals with cystic fibrosis with mutations nonresponsive to current cystic fibrosis transmembrane conductance regulator modulators.Semantic proximity Read ↗

Cystic fibrosis: therapies targeting specific gene defects.Semantic proximity Read ↗

Cystic fibrosis transmembrane conductance regulator intracellular processing, trafficking, and opportunities for mutation-specific treatment.Semantic proximity Read ↗

Emerging medicines to improve the basic defect in cystic fibrosis.Semantic proximity Read ↗

Therapeutic Approaches for Patients with Cystic Fibrosis Not Eligible for Current CFTR Modulators.Semantic proximity Read ↗

Targeted therapy for cystic fibrosis: cystic fibrosis transmembrane conductance regulator mutation-specific pharmacologic strategies.Semantic proximity Read ↗

A new era in the treatment of cystic fibrosis: correction of the underlying CFTR defect.Semantic proximity Read ↗

Use of protein repair therapy in the treatment of cystic fibrosis.Semantic proximity Read ↗

Therapies directed at the basic defect in cystic fibrosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.